Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The continual increase in global cancer incidence has created a huge need for new and more effective cancer drugs. However, success is often limited by the heterogeneity among patients, which frequently leads to the failure of patients to respond to a drug together with toxic side effects. Personalised medicine uses our advancing molecular understanding of disease to provide the most efficient medical care for individual patients, depending on their unique clinical, genetic and environmental state. Various types of biomarkers assist this process by enabling prediction of clinical outcome on treatment, or measuringeffect of treatmentwhichis then correlated with a clinical endpoint. Omics technologies such as genomics, transcriptomics and proteomics are crucially important in the personalised medicine approach as they enable the analysis of multiple and large datasets to stratify patients into responder subgroups.

Original publication

DOI

10.1002/9780470015902.a0025180

Type

Journal article

Journal

Encyclopedia of Life Sciences

Publisher

John Wiley & Sons

Publication Date

18/11/2013

Pages

1 - 10

Total pages

10